S Ghorbian1, I Jahanzad, G R Javadi, E Sakhinia. 1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran, ghorbian20@yahoo.com.
Abstract
PURPOSE: Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in formalin-fixed, paraffin-embedded (FFPE) tissue of patients with B-cell non-Hodgkin lymphomas (B-NHL). MATERIALS AND METHODS: This study was performed on samples from 70 patients with B-NHL, including two cases of follicular lymphoma (FL), 20 cases of diffuse large B-cell lymphoma (DLBCL), one case of mantle cell lymphoma (MCL), and 47 cases of B-cell neoplasm (non-classified), which had been previously assessed for complete IGH clonality, and failure to clarify gene rearrangements. We used a gold standard multiplex PCR protocol provided by European Biomedicine and Health (BIOMED-2) Concerted Action Project BMH4-CT98-3936 for improvement of diagnosis and analysis of clonality gene rearrangement in lymphoma malignancies. RESULTS: Our results revealed a total positive monoclonality of 89 % (62/70) in Igκ, Igλ, and 11.4 % (8/70) polyclonality in gene rearrangements assay. The samples with positive clonality consisting (Igκ: 45 %, Igλ: 55 %) in DLBCL, (Igκ: 100 %) in FL, (Igλ: 100 %) in MCL, and (Igκ: 47 %, Igλ: 36 %) in B-cell neoplasm non-classified. None of the incomplete IGH D-J immunoglobulin gene families (0 %) showed monoclonality, and all samples demonstrated polyclonality pattern. CONCLUSIONS: Our findings on FFPE tissue revealed that immunoglobulin light chains clonality gene rearrangements assays using BIOMED-2 protocol, could be considered a valuable and reliable method for clonality detection, particularly in cases of failure of complete IGH gene rearrangements analysis. Clonal Ig gene rearrangements assay is applicable for routine diagnostic testing of lymphoproliferative disorders and as a reliable method for differentiating between malignant and benign lymphoma disorders.
PURPOSE: Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in formalin-fixed, paraffin-embedded (FFPE) tissue of patients with B-cell non-Hodgkin lymphomas (B-NHL). MATERIALS AND METHODS: This study was performed on samples from 70 patients with B-NHL, including two cases of follicular lymphoma (FL), 20 cases of diffuse large B-cell lymphoma (DLBCL), one case of mantle cell lymphoma (MCL), and 47 cases of B-cell neoplasm (non-classified), which had been previously assessed for complete IGH clonality, and failure to clarify gene rearrangements. We used a gold standard multiplex PCR protocol provided by European Biomedicine and Health (BIOMED-2) Concerted Action Project BMH4-CT98-3936 for improvement of diagnosis and analysis of clonality gene rearrangement in lymphoma malignancies. RESULTS: Our results revealed a total positive monoclonality of 89 % (62/70) in Igκ, Igλ, and 11.4 % (8/70) polyclonality in gene rearrangements assay. The samples with positive clonality consisting (Igκ: 45 %, Igλ: 55 %) in DLBCL, (Igκ: 100 %) in FL, (Igλ: 100 %) in MCL, and (Igκ: 47 %, Igλ: 36 %) in B-cell neoplasm non-classified. None of the incomplete IGH D-J immunoglobulin gene families (0 %) showed monoclonality, and all samples demonstrated polyclonality pattern. CONCLUSIONS: Our findings on FFPE tissue revealed that immunoglobulin light chains clonality gene rearrangements assays using BIOMED-2 protocol, could be considered a valuable and reliable method for clonality detection, particularly in cases of failure of complete IGH gene rearrangements analysis. Clonal Ig gene rearrangements assay is applicable for routine diagnostic testing of lymphoproliferative disorders and as a reliable method for differentiating between malignant and benign lymphoma disorders.
Authors: Claudia Mannu; Anna Gazzola; Francesco Bacci; Elena Sabattini; Carlo Sagramoso; Fernando Roncolato; Maura Rossi; Maria Antonella Laginestra; Maria Rosaria Sapienza; Claudio Agostinelli; Antonio De Leo; Milena Piccioli; Simona Righi; Patrizia Artioli; Luigi Chilli; Gianpaolo Da Pozzo; Giuseppe De Biase; Federica Sandri; Stefano A Pileri; Pier Paolo Piccaluga Journal: Am J Blood Res Date: 2011-09-12
Authors: J H J M van Krieken; A W Langerak; E A Macintyre; M Kneba; E Hodges; R Garcia Sanz; G J Morgan; A Parreira; T J Molina; J Cabeçadas; P Gaulard; B Jasani; J F Garcia; M Ott; M L Hannsmann; F Berger; M Hummel; F Davi; M Brüggemann; F L Lavender; E Schuuring; P A S Evans; H White; G Salles; P J T A Groenen; P Gameiro; Ch Pott; J J M van Dongen Journal: Leukemia Date: 2006-12-14 Impact factor: 11.528
Authors: Tomasz Szczepański; Marja J Willemse; Bas Brinkhof; Elisabeth R van Wering; Mirjam van der Burg; Jacques J M van Dongen Journal: Blood Date: 2002-04-01 Impact factor: 22.113
Authors: David González; Mirjam van der Burg; Ramón García-Sanz; James A Fenton; Anton W Langerak; Marcos González; Jacques J M van Dongen; Jesus F San Miguel; Gareth J Morgan Journal: Blood Date: 2007-07-18 Impact factor: 22.113